Miyakawa 2021 [B].

Study characteristics
Patient Sampling	Comparative study of 4 Ag tests; Miyakawa 2021 [A] reports full study characteristics and QUADAS.
Patient characteristics and setting	Comparative study of 4 Ag tests; Miyakawa 2021 [A] reports full study characteristics and QUADAS.
Index tests	Test name: [A] authors' own‐developed Ag‐RDT (YCU‐FF LFIA (Ag‐RDT); now marketed as FUJIFILM COVID‐19 Ag Test www.fujifilm.com/jp/en/news/hq/358e) [B] Panbio COVID‐19 Ag Rapid Test [C] Espline SARS‐CoV‐2 [D] STANDARD Q COVID‐19 Ag Also evaluated [E] SARS‐CoV‐2 Rapid Antigen Test from Roche. Data not included as this is understood to be the same test as 'STANDARD Q' from SD Biosensor Manufacturer: [A] FUJIFILM [B] Abbott [C] Fujirebio [D] SD Biosensor Antibody: [A] SARS‐CoV‐2 nucleocapsid protein; [B] to [D] not described Ag target: [A] specific monoclonal antibodies against the SARS‐CoV‐2 nucleocapsid protein; [B] to [D] not described Test method: [A] CGIA with silver ions; [B] to [D] not described Samples used: NP (collection not described) Transport media: VTM (no further detail reported) Sample storage: stored at −80 °C until used (timing not reported) Test operator: not reported; "test line interpretations … made by at least two people" Definition of test positivity: appearance of visible line Blinding reported: not stated Timing of samples: not reported
Target condition and reference standard(s)	Comparative study of 4 Ag tests; Miyakawa 2021 [A] reports full study characteristics and QUADAS.
Flow and timing	Comparative study of 4 Ag tests; Miyakawa 2021 [A] reports full study characteristics and QUADAS.
Comparative
Notes	Comparative study of 4 Ag tests; Miyakawa 2021 [A] reports full study characteristics and QUADAS.